研究者詳細 - 國定　俊之

論文 - 國定　俊之

分割表示 556 件中 301 - 320 件目／全件表示 >>

Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma 査読

Tomohiro Fujiwara, Koji Uotani, Aki Yoshida, Takuya Morita, Yutaka Nezu, Eisuke Kobayashi, Akihiko Yoshida, Takenori Uehara, Toshinori Omori, Kazuhisa Sugiu, Tadashi Komatsubara, Ken Takeda, Toshiyuki Kunisada, Machiko Kawamura, Akira Kawai, Takahiro Ochiya, Toshifumi Ozaki

ONCOTARGET 8 ( 20 ) 33375 - 33392 2017年5月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：IMPACT JOURNALS LLC

Background: Emerging evidence has suggested that circulating microRNAs (miRNAs) in body fluids have novel diagnostic and prognostic significance for patients with malignant diseases. The lack of useful biomarkers is a crucial problem of bone and soft tissue sarcomas; therefore, we investigated the circulating miRNA signature and its clinical relevance in osteosarcoma.
Methods: Global miRNA profiling was performed using patient serum collected from a discovery cohort of osteosarcoma patients and controls and cell culture media. The secretion of the detected miRNAs from osteosarcoma cells and clinical relevance of serum miRNA levels were evaluated using in vitro and in vivo models and a validation patient cohort.
Results: Discovery screening identified 236 serum miRNAs that were highly expressed in osteosarcoma patients compared with controls, and eight among these were also identified in the cell culture media. Upregulated expression levels of miR-17-5p and miR-25-3p were identified in osteosarcoma cells, and these were abundantly secreted into the culture media in tumor-derived exosomes. Serum miR-25-3p levels were significantly higher in osteosarcoma patients than in control individuals in the validation cohort, with favorable sensitivity and specificity compared with serum alkaline phosphatase. Furthermore, serum miR-25-3p levels at diagnosis were correlated with patient prognosis and reflected tumor burden in both in vivo models and patients; these associations were more sensitive than those of serum alkaline phosphatase.
Conclusions: Serum-based circulating miR-25-3p may serve as a non-invasive blood-based biomarker for tumor monitoring and prognostic prediction in osteosarcoma patients.

DOI： 10.18632/oncotarget.16498

Web of Science

PubMed

researchmap

鎖骨骨切りにより切除可能となった腕神経叢発生脂肪性腫瘍の治療経験

横尾賢, 国定俊之, 藤原智洋, 長谷井嬢, 尾崎敏文

中部日本整形外科災害外科学会雑誌 60 ( 春季学会 ) 193 - 193 2017年4月

骨肉腫患者の組織ならびに血中におけるoncogenic miR-25-3pの臨床病理学的意義

藤原智洋, 魚谷弘二, 吉田晶, 森田卓也, 清野正普, 国定俊之, 根津悠, 小林英介, 川井章, 落谷孝広, 尾崎敏文

日本整形外科学会雑誌 91 ( 3 ) S707 - S707 2017年3月

骨・軟部肉腫切除術における感染リスクファクターの検討

長谷井嬢, 望月雄介, 小松原将, 国定俊之, 藤原智洋, 魚谷弘二, 杉生和久, 尾崎敏文

日本整形外科学会雑誌 91 ( 2 ) S598 - S598 2017年3月

肩関節周辺悪性骨腫瘍切除後の肩関節再建手術腫瘍型上腕骨人工骨頭置換術に対する軟部組織再建術

国定俊之, 藤原智洋, 長谷井嬢, 尾崎敏文

日本整形外科学会雑誌 91 ( 2 ) S400 - S400 2017年3月

骨・軟部腫瘍における術中CTナビゲーション手術の正確性と臨床評価

藤原智洋, 国定俊之, 長谷井嬢, 吉田晶, 尾崎敏文

日本整形外科学会雑誌 91 ( 3 ) S711 - S711 2017年3月

Verification of Implant Surface Modification by a Novel Processing Method

Okada Yoshiki, Abe Nobuhiro, Hisamori Noriyuki, Kaneeda Toshiaki, Moriyama Shigeaki, Ohmori Hitoshi, Mizutani Masayoshi, Yanai Hiroyuki, Nakashima Yoshio, Yokoyama Yusuke, Ozaki Toshifumi

Acta Medica Okayama 71 ( 1 ) 49 - 57 2017年2月

記述言語：英語出版者・発行元：Okayama University Medical School

Metals have been used clinically as biomaterials, especially in the orthopaedic and dental fields. Metals used as implants wear at contact surfaces, producing metal particles and metal ions that may be harmful. Newly developed metal implants and methods of implant surface modification are currently under scrutiny. We evaluated the use of electrolytic in-process dressing (ELID) as a surface finishing method for metal implants. Metal implants processed using the ELID method (ELID group) or not processed (Non-ELID group) were inserted surgically into rabbit femurs. The rabbits were sacrificed postoperatively over a 24-week period. We assessed the concentrations of the cytokines, interleukin (IL)-1β, IL-6, and tumor necrosis factor-α, the resistance to implant pull-out, and histopathology at the implant site. There was no significant difference between the groups regarding the cytokine concentrations or implant pull-out resistance. Many particles indicating wear around the implant were noted in the Non-ELID group (n=10) but not the ELID group (n=13), while a fibrous membrane adhering to the every implant was noted in the ELID group. The formation of a fibrous membrane rather than metal particles in the ELID group may indicate improved biocompatibility, and it suggests that ELID may prevent corrosion in the areas of contact.

DOI： 10.18926/AMO/54825

CiNii Article

CiNii Books

researchmap

Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies 査読

Mitsuru Takahashi, Shunji Takahashi, Nobuhito Araki, Hideshi Sugiura, Takafumi Ueda, Tsukasa Yonemoto, Hideo Morioka, Hiroaki Hiraga, Toru Hiruma, Toshiyuki Kunisada, Akihiko Matsumine, Masashi Shimura, Akira Kawai

ONCOLOGIST 22 ( 8 ) 979 - 988 2017年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：WILEY

Background. Trabectedin is reported as effective, especially against translocation-related sarcomas (TRSs) after failure of or intolerance to standard chemotherapy. We conducted two phase II studies of TRS, confirming high efficacy of 1.2 mg/m(2) trabectedin. The updated data of 66 patients in these studies was integrated to evaluate the efficacy of trabectedin against each histological subtype, and analyze final overall survival (OS).
Methods. Trabectedin was administered on day one of a 21-day cycle. Efficacy was assessed using progression-free survival (PFS), OS, and best overall response. An analysis of OS and PFS was performed for subgroups divided by baseline lymphocyte count (<1,000/mu L, >= 1,000/mu L) or number of previous chemotherapy regimens (0, 1, 2, >= 3 regimens), and a Weibull parametric model was used to estimate the numerical relationship between lymphocyte count and PFS and OS.
Results. Median PFS and OS in overall patients were 5.6 (95% confidence interval [CI]: 4.1-7.3) and 17.5 months (95% CI: 12.6-23.6), respectively. PFS in the myxoid and round-cell liposarcoma (MRCL) group (7.4 months [95% CI: 5.6-11.1]) was longer than in the other subtypes. The response rate was also highest in the MRCL group. Median OS was longer in patients with baseline lymphocyte counts >= 1,000/mu L than in those with counts of <1,000/mu L, but median PFS was not different between the two subgroups.
Conclusion. Our updated and pooled data showed that trabectedin exerted prolonged disease control and antitumor effects in patients with advanced TRS, especially in MRCL. We consider that the subgroup analyses also provide important information for trabectedin treatment in patients with TRS.

DOI： 10.1634/theoncologist.2016-0064

Web of Science

PubMed

researchmap

Neurological Recovery after Posterior Spinal Surgery in Patients with Metastatic Epidural Spinal Cord Compression 査読

Noriyuki Watanabe, Yoshihisa Sugimoto, Masato Tanaka, Tetsuro Mazaki, Shinya Arataki, Tomoyuki Takigawa, Masaki Kataoka, Toshiyuki Kunisada, Toshifumi Ozaki

ACTA MEDICA OKAYAMA 70 ( 6 ) 449 - 453 2016年12月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：OKAYAMA UNIV MED SCHOOL

Metastatic epidural spinal cord compression (MESCC) is a common complication in patients with a malignant tumor, but it is difficult to decide the proper time to perform the necessary surgery. Here we analyzed the prognostic factors for postoperative walking ability. We retrospectively reviewed the cases of 112 MESCC patients treated surgically at our institute and divided them into ambulatory (n = 88) and non-ambulatory (n = 24) groups based on their American Spinal Injury Association (ASIA) Impairment Scale grades at the final follow-up. We also classified the patients preoperatively using the revised Tokuhashi score. We assessed the correlation between preoperative or intraoperative factors and postoperative walking ability in both groups. Of the 10 patients classified preoperatively as grade A or B, 2 (20) were ambulatory at the final follow-up. Of the 102 patients classified preoperatively as grade C, D or E, 86 (84) were ambulatory at the final follow-up (p < 0.001). There were no significant differences between the groups in the average total Tokuhashi score. Our analysis revealed that the severity of paralysis significantly affects neurological recovery in patients with MESCC. Patients with MESCC should receive surgery before the preoperative ASIA Impairment Scale grade falls below grade C.

DOI： 10.18926/AMO/54807

Web of Science

PubMed

researchmap

骨腫瘍切除後の骨欠損に対する配向連通気孔構造を有する人工骨移植の治療経験

清野正普, 国定俊之, 藤原智洋, 長谷井嬢, 杉生和久, 魚谷弘二, 森田卓也, 小松原将, 望月雄介, 尾崎敏文

移植 51 ( 6 ) 527 - 527 2016年12月